Brief: Spyre Therapeutics Inc - Skyline Trial In UC Completes SPY001 Enrollment Ahead Of Schedule
12/01/2026 13:05
Jan 12 (Reuters) - Spyre Therapeutics Inc SYRE.O: SPYRE THERAPEUTICS INC - SKYLINE TRIAL IN UC COMPLETES SPY001 ENROLLMENT AHEAD OF SCHEDULE SPYRE THERAPEUTICS INC - SKYWAY TRIAL READOUTS EXPECTED IN 4Q 2026 SPYRE THERAPEUTICS INC: SKYLINE PART A READOUTS ACCELERATED, NOW EXPECTED TO START IN Q2 Source text: ID:nGNX9Zlr7k Further company coverage: SYRE.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Spyre Therapeutics
See all newsU.S. STOCKS ON THE MOVE-Becton Dickinson, Constellation Energy, Marvell
U.S. STOCKS ON THE MOVE-Constellation Energy, AMD
U.S. STOCKS ON THE MOVE-MYR Group, Spyre Therapeutics, AMD
Spyre Therapeutics slips on $350 mln share sale
Brief: Spyre Therapeutics Announces Pricing Of $350.0 Million Public Offering Of Common Stock